Vaxxinity (VAXX) Competitors $0.0050 -0.03 (-85.71%) As of 03/28/2025 09:42 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrendsBuy This Stock VAXX vs. PRFX, SBFM, ENTO, PLRZ, DRMA, TCRT, QLGN, EYEN, PALI, and EVAXShould you be buying Vaxxinity stock or one of its competitors? The main competitors of Vaxxinity include PainReform (PRFX), Sunshine Biopharma (SBFM), Entero Therapeutics (ENTO), Polyrizon (PLRZ), Dermata Therapeutics (DRMA), Alaunos Therapeutics (TCRT), Qualigen Therapeutics (QLGN), Eyenovia (EYEN), Palisade Bio (PALI), and Evaxion Biotech A/S (EVAX). These companies are all part of the "pharmaceutical products" industry. Vaxxinity vs. PainReform Sunshine Biopharma Entero Therapeutics Polyrizon Dermata Therapeutics Alaunos Therapeutics Qualigen Therapeutics Eyenovia Palisade Bio Evaxion Biotech A/S Vaxxinity (NASDAQ:VAXX) and PainReform (NASDAQ:PRFX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, community ranking, analyst recommendations, media sentiment, profitability, institutional ownership and risk. Do institutionals and insiders hold more shares of VAXX or PRFX? 82.9% of Vaxxinity shares are owned by institutional investors. Comparatively, 37.3% of PainReform shares are owned by institutional investors. 64.1% of Vaxxinity shares are owned by insiders. Comparatively, 34.4% of PainReform shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more volatility and risk, VAXX or PRFX? Vaxxinity has a beta of -17.57, indicating that its share price is 1,857% less volatile than the S&P 500. Comparatively, PainReform has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500. Is VAXX or PRFX more profitable? Vaxxinity's return on equity of 0.00% beat PainReform's return on equity.Company Net Margins Return on Equity Return on Assets VaxxinityN/A N/A N/A PainReform N/A -450.64%-241.33% Do analysts rate VAXX or PRFX? PainReform has a consensus price target of $8.00, suggesting a potential upside of 268.66%. Given PainReform's stronger consensus rating and higher probable upside, analysts plainly believe PainReform is more favorable than Vaxxinity.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaxxinity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00PainReform 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the MarketBeat Community prefer VAXX or PRFX? Vaxxinity received 2 more outperform votes than PainReform when rated by MarketBeat users. However, 75.00% of users gave PainReform an outperform vote while only 38.46% of users gave Vaxxinity an outperform vote. CompanyUnderperformOutperformVaxxinityOutperform Votes538.46% Underperform Votes861.54% PainReformOutperform Votes375.00% Underperform Votes125.00% Does the media prefer VAXX or PRFX? In the previous week, PainReform had 1 more articles in the media than Vaxxinity. MarketBeat recorded 1 mentions for PainReform and 0 mentions for Vaxxinity. PainReform's average media sentiment score of 1.87 beat Vaxxinity's score of 0.00 indicating that PainReform is being referred to more favorably in the news media. Company Overall Sentiment Vaxxinity Neutral PainReform Very Positive Which has better valuation & earnings, VAXX or PRFX? PainReform is trading at a lower price-to-earnings ratio than Vaxxinity, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaxxinityN/AN/A-$56.93M-$0.45-0.01PainReformN/AN/A-$9.34M-$147.33-0.01 SummaryVaxxinity and PainReform tied by winning 7 of the 14 factors compared between the two stocks. Remove Ads Get Vaxxinity News Delivered to You Automatically Sign up to receive the latest news and ratings for VAXX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VAXX vs. The Competition Export to ExcelMetricVaxxinityPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$634,000.00$6.90B$5.63B$7.84BDividend YieldN/A2.74%4.57%4.01%P/E Ratio-0.017.1723.3318.67Price / SalesN/A218.10387.5490.66Price / CashN/A65.6738.1634.64Price / Book0.056.396.894.23Net Income-$56.93M$142.12M$3.20B$247.15M7 Day PerformanceN/A-5.06%-2.98%-2.18%1 Month PerformanceN/A-7.49%1.63%-5.68%1 Year PerformanceN/A-10.91%9.44%-0.74% Vaxxinity Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VAXXVaxxinityN/A$0.01-85.7%N/A-99.3%$634,000.00N/A-0.0190Gap DownPRFXPainReform2.5 of 5 stars$2.84-2.6%$8.00+182.2%-70.2%$2.48MN/A-0.024Upcoming EarningsPositive NewsSBFMSunshine Biopharma2.3446 of 5 stars$2.03-1.7%$15.00+640.7%-66.9%$2.48M$32.96M-0.013Upcoming EarningsShort Interest ↑Gap UpENTOEntero Therapeutics0.7575 of 5 stars$0.52-2.3%N/AN/A$2.48MN/A0.009Short Interest ↑Positive NewsGap DownPLRZPolyrizonN/A$0.57-10.9%N/AN/A$2.39MN/A0.00N/ANews CoverageGap DownDRMADermata Therapeutics2.5461 of 5 stars$1.17flat$6.00+412.8%-80.4%$2.39MN/A-0.078Short Interest ↓News CoverageTCRTAlaunos Therapeutics1.2293 of 5 stars$1.49+1.0%N/A-91.9%$2.38M$7,000.000.0040Short Interest ↓News CoveragePositive NewsQLGNQualigen TherapeuticsN/A$3.14+1.3%N/A-81.0%$2.31M$4.98M0.0050Upcoming EarningsPositive NewsEYENEyenovia2.3962 of 5 stars$1.66-3.2%$2.00+20.8%-98.6%$2.31M$31,832.00-0.0340Short Interest ↓PALIPalisade Bio2.4166 of 5 stars$0.82-4.1%$23.00+2,708.3%-88.3%$2.27M$250,000.00-0.0610Earnings ReportShort Interest ↑EVAXEvaxion Biotech A/S2.6017 of 5 stars$1.89+1.0%$20.00+958.8%-89.0%$2.20M$3.30M-1.2960Short Interest ↓News Coverage Remove Ads Related Companies and Tools Related Companies PainReform Competitors Sunshine Biopharma Competitors Entero Therapeutics Competitors Polyrizon Competitors Dermata Therapeutics Competitors Alaunos Therapeutics Competitors Qualigen Therapeutics Competitors Eyenovia Competitors Palisade Bio Competitors Evaxion Biotech A/S Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VAXX) was last updated on 3/29/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxxinity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxxinity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VAXX Stock Free VAXX Stock Alerts